The Japanese Encephalitis Antigenic Complex Viruses: From Structure to Immunity

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Oct 27

PMID 36298768

Authors

Baldeep Khare

Richard J Kuhn

Affiliations

Soon will be listed here.

Abstract

In the last three decades, several flaviviruses of concern that belong to different antigenic groups have expanded geographically. This has resulted in the presence of often more than one virus from a single antigenic group in some areas, while in Europe, Africa and Australia, additionally, multiple viruses belonging to the Japanese encephalitis (JE) serogroup co-circulate. Morphological heterogeneity of flaviviruses dictates antibody recognition and affects virus neutralization, which influences infection control. The latter is further impacted by sequential infections involving diverse flaviviruses co-circulating within a region and their cross-reactivity. The ensuing complex molecular virus-host interplay leads to either cross-protection or disease enhancement; however, the molecular determinants and mechanisms driving these outcomes are unclear. In this review, we provide an overview of the epidemiology of four JE serocomplex viruses, parameters affecting flaviviral heterogeneity and antibody recognition, host immune responses and the current knowledge of the cross-reactivity involving JE serocomplex flaviviruses that leads to differential clinical outcomes, which may inform future preventative and therapeutic interventions.

Citing Articles

Epidemiological Features, Clinical Symptoms, and Environmental Risk Factors for Notifiable Japanese Encephalitis in Taiwan From 2008 to 2020: Retrospective Study.

Lin F, Chou Y, Hsieh C, Yu C JMIR Public Health Surveill. 2025; 11:e63053.

PMID: 39881432 PMC: 11793194. DOI: 10.2196/63053.

Key virulence factors responsible for differences in pathogenicity between clinically proven live-attenuated Japanese encephalitis vaccine SA14-14-2 and its pre-attenuated highly virulent parent SA14.

Song B, Yun S, Goldhardt J, Kim J, Lee Y PLoS Pathog. 2025; 21(1):e1012844.

PMID: 39775684 PMC: 11741592. DOI: 10.1371/journal.ppat.1012844.

Advancements in nanoparticle-based vaccine development against Japanese encephalitis virus: a systematic review.

Adugna T, Niu Q, Guan G, Du J, Yang J, Tian Z Front Immunol. 2025; 15:1505612.

PMID: 39759527 PMC: 11695416. DOI: 10.3389/fimmu.2024.1505612.

West Nile Virus in a changing climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges - a comprehensive review.

Singh P, Khatib M, Ballal S, Kaur M, Nathiya D, Sharma S Emerg Microbes Infect. 2024; 14(1):2437244.

PMID: 39614679 PMC: 11703391. DOI: 10.1080/22221751.2024.2437244.

A specific domain within the 3' untranslated region of Usutu virus confers resistance to the exonuclease ISG20.

Zoladek J, El Kazzi P, Caval V, Vivet-Boudou V, Cannac M, Davies E Nat Commun. 2024; 15(1):8528.

PMID: 39358425 PMC: 11447015. DOI: 10.1038/s41467-024-52870-w.

References

Schoggins J, Rice C . Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2012; 1(6):519-25. PMC: 3274382. DOI: 10.1016/j.coviro.2011.10.008. View

Beasley D, Whiteman M, Zhang S, Huang C, Schneider B, Smith D . Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol. 2005; 79(13):8339-47. PMC: 1143769. DOI: 10.1128/JVI.79.13.8339-8347.2005. View

Saiz J, Martin-Acebes M, Blazquez A, Escribano-Romero E, Poderoso T, Jimenez de Oya N . Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation. Virulence. 2021; 12(1):1145-1173. PMC: 8043182. DOI: 10.1080/21505594.2021.1908740. View

Zicari S, Arakelyan A, Fitzgerald W, Zaitseva E, Chernomordik L, Margolis L . Evaluation of the maturation of individual Dengue virions with flow virometry. Virology. 2015; 488:20-7. PMC: 4744565. DOI: 10.1016/j.virol.2015.10.021. View

Zheng X, Yu X, Wang Y, Cui M, Wang R, Yin C . Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain. Infect Genet Evol. 2020; 85:104443. PMC: 7324926. DOI: 10.1016/j.meegid.2020.104443. View

Bressanelli S, Stiasny K, Allison S, Stura E, Duquerroy S, Lescar J . Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004; 23(4):728-38. PMC: 380989. DOI: 10.1038/sj.emboj.7600064. View

WENGLER G . Cell-associated West Nile flavivirus is covered with E+pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J Virol. 1989; 63(6):2521-6. PMC: 250716. DOI: 10.1128/JVI.63.6.2521-2526.1989. View

Diamond M, Gale Jr M . Cell-intrinsic innate immune control of West Nile virus infection. Trends Immunol. 2012; 33(10):522-30. PMC: 3461102. DOI: 10.1016/j.it.2012.05.008. View

Wallace M, Smith D, Broom A, MacKenzie J, Hall R, Shellam G . Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol. 2003; 84(Pt 7):1723-1728. DOI: 10.1099/vir.0.18980-0. View

10.

Kuhn R, Zhang W, Rossmann M, Pletnev S, Corver J, Lenches E . Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5):717-25. PMC: 4152842. DOI: 10.1016/s0092-8674(02)00660-8. View

11.

Bakonyi T, Ivanics E, Erdelyi K, Ursu K, Ferenczi E, Weissenbock H . Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006; 12(4):618-23. PMC: 3294705. DOI: 10.3201/eid1204.051379. View

12.

Yu I, Zhang W, Holdaway H, Li L, Kostyuchenko V, Chipman P . Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008; 319(5871):1834-7. DOI: 10.1126/science.1153264. View

13.

Martin-Acebes M, Blazquez A, Canas-Arranz R, Vazquez-Calvo A, Merino-Ramos T, Escribano-Romero E . A recombinant DNA vaccine protects mice deficient in the alpha/beta interferon receptor against lethal challenge with Usutu virus. Vaccine. 2016; 34(18):2066-73. DOI: 10.1016/j.vaccine.2016.03.015. View

14.

Barnard T, Abram Q, Lin Q, Wang A, Sagan S . Molecular Determinants of Flavivirus Virion Assembly. Trends Biochem Sci. 2021; 46(5):378-390. DOI: 10.1016/j.tibs.2020.12.007. View

15.

Lobigs M, Pavy M, Hall R . Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine. 2003; 21(15):1572-9. DOI: 10.1016/s0264-410x(02)00743-0. View

16.

Merino-Ramos T, Blazquez A, Escribano-Romero E, Canas-Arranz R, Sobrino F, Saiz J . Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PLoS One. 2014; 9(9):e108056. PMC: 4168257. DOI: 10.1371/journal.pone.0108056. View

17.

Plevka P, Battisti A, Junjhon J, Winkler D, Holdaway H, Keelapang P . Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres. EMBO Rep. 2011; 12(6):602-6. PMC: 3128282. DOI: 10.1038/embor.2011.75. View

18.

Erra E, Kantele A . The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev Vaccines. 2015; 14(9):1167-79. DOI: 10.1586/14760584.2015.1061939. View

19.

Crill W, Chang G . Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004; 78(24):13975-86. PMC: 533943. DOI: 10.1128/JVI.78.24.13975-13986.2004. View

20.

Li L, Lok S, Yu I, Zhang Y, Kuhn R, Chen J . The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008; 319(5871):1830-4. DOI: 10.1126/science.1153263. View